Immunotherapy in the First-Line Setting in Wild-Type NSCLC

Immunotherapy in the First-Line Setting in Wild-Type NSCLC

Treatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in first-line stage IV NSCLC, organized by the following...

Full description

Bibliographic Details
Main Authors:	Marie-Hélène Denault, Barbara Melosky
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Current Oncology
Subjects:	NSCLC PD-L1 first-line immunotherapy non-small cell lung cancer squamous
Online Access:	https://www.mdpi.com/1718-7729/28/6/378

Similar Items

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
by: Edoardo Lenci, et al.
Published: (2021-03-01)

Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
by: Min Wang, et al.
Published: (2023-03-01)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
by: Mette T. Mouritzen, et al.
Published: (2021-09-01)

The Landscape of Immunotherapy Resistance in NSCLC
by: Daniele Frisone, et al.
Published: (2022-04-01)

Erratum: The landscape of immunotherapy resistance in NSCLC
by: Frontiers Production Office
Published: (2023-04-01)

Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
by: Veronika Pelicon, et al.
Published: (2023-06-01)

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
by: Romain-David Seban, et al.
Published: (2020-08-01)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Edith Borcoman, et al.
Published: (2021-05-01)

First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
by: Andrea Spini, et al.
Published: (2021-12-01)

Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
by: Luigi Della Gravara, et al.
Published: (2021-06-01)

Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
by: Ana Oitabén, et al.
Published: (2022-05-01)

Immunotherapy in NSCLC Patients with Brain Metastases
by: Silvia Buriolla, et al.
Published: (2022-06-01)

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
by: Jie Mei, et al.
Published: (2022-07-01)

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
by: Francesco Facchinetti, et al.
Published: (2020-09-01)

High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
by: Brane Grambozov, et al.
Published: (2022-01-01)

Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
by: Amine Bouhamama, et al.
Published: (2023-05-01)

A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative
by: Tao Li, et al.
Published: (2024-02-01)

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
by: Pedro De Marchi, et al.
Published: (2024-01-01)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
by: Dolores Isla, et al.
Published: (2023-08-01)

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
by: Yanxia Liu, et al.
Published: (2022-11-01)

<sup>18</sup>F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
by: Giulia Polverari, et al.
Published: (2020-05-01)

Impact of the pretreatment prognostic nutritional index on the survival after first‐line immunotherapy in non‐small‐cell lung cancer patients
by: Yuka Oku, et al.
Published: (2023-07-01)

Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
by: Florian Eichhorn, et al.
Published: (2021-04-01)

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database
by: Heidi A. I. Grosjean, et al.
Published: (2021-10-01)

MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?
by: Anna Grenda, et al.
Published: (2024-02-01)

Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression
by: Lianxiang Luo, et al.
Published: (2022-11-01)

Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy
by: Sara Baglivo, et al.
Published: (2021-06-01)

Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
by: Xabier Mielgo-Rubio, et al.
Published: (2021-09-01)

Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
by: Mingye Zhao, et al.
Published: (2022-09-01)

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression
by: Timothy Rajakumar, MD, PhD, et al.
Published: (2022-08-01)

An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
by: Saurav Verma, et al.
Published: (2024-03-01)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022-01-01)

Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis
by: Birgitte Bjørnhart, et al.
Published: (2022-03-01)

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
by: Wei Li, et al.
Published: (2022-11-01)

The role of chemoradiotherapy and immunotherapy in stage III NSCLC
by: Zsuzsanna Orosz, et al.
Published: (2024-04-01)

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
by: Zhichao Liu, et al.
Published: (2022-09-01)

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
by: Lan-Lan Pang, et al.
Published: (2023-01-01)

Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
by: Vianey Rodriguez-Lara, et al.
Published: (2023-10-01)

Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
by: Yiyi Huang, et al.
Published: (2023-09-01)

Erratum: Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
by: Frontiers Production Office
Published: (2024-01-01)